Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
NCT04435782 · Actelion · PHASE4 · terminated · last registry update 2025-03-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The Sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate.” | – | Registry record, Actelion |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGIR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-27Phase 3 first posted: University Hospital, Rouen, Iloprost + Placebo (NCT07498309)
- 2026-03-19Phase 3 first posted: Insmed Incorporated, Treprostinil Palmitil Inhalation Powder + Placebo (NCT07481981)
- 2025-12-16Phase 3 first posted: Liquidia Technologies, Inc., L606 + Placebo (NCT07285655)
- 2025-12-03Results posted on the registry: Mayo Clinic, Treprostinil (NCT05564637)
- 2025-11-18Phase 3 first posted: Insmed Incorporated, Treprostinil Palmitil Inhalation Powder + Placebo (NCT07234032)
- 2025-09-17Phase 3 first posted: Insmed Incorporated, Treprostinil Palmitil Inhalation Powder + Placebo (NCT07179380)
- 2025-07-31Results posted on the registry: Aerogen Pharma Limited, VentaProst (NCT03122730)
- 2025-07-31Results posted on the registry: Aerogen Pharma Limited, VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (NCT04452669)
- 2025-05-25Results posted on the registry: Civi Biopharma, Inc., Placebo IV infusion + Iloprost Injection, for intravenous use (NCT03867097)
- 2025-05-25Results posted on the registry: Civi Biopharma, Inc., Placebo IV infusion + Iloprost Injection, for intravenous use (NCT04040322)
- 2025-02-04Also stopped (terminated): Actelion, Inhaled Iloprost (5 μg) + Inhaled Placebo (NCT00302211)
- 2024-11-20Results posted on the registry: Actelion, Selexipag (NCT04565990)
- 2024-11-12Results posted on the registry: University of Edinburgh, Isosorbide Mononitrate XL (ISMN) + Cilostazol (NCT03451591)
- 2024-11-01Results posted on the registry: United Therapeutics, Treprostinil Inhalation Powder (NCT03950739)
- 2024-10-15Also stopped (terminated): Duke University, Inhaled Iloprost (NCT02170519)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-07-30Results posted on the registry: Liquidia Technologies, Inc., LIQ861 Inhaled Treprostinil (NCT03399604)
- 2024-06-21Also stopped (terminated): Actelion, Selexipag + Placebo (NCT03689244)
- 2024-06-18Also stopped (terminated): United Therapeutics, treprostinil diethanolamine (NCT00848107)
- 2024-05-17Also stopped (withdrawn): National Cancer Institute (NCI), Iloprost + Placebo Administration (NCT05411107)
- 2024-05-08Results posted on the registry: Actelion, Selexipag + Placebo (NCT03942211)
- 2024-05-08Also stopped (terminated): Actelion, Selexipag + Placebo (NCT03942211)
- 2024-04-05Phase 3 first posted: AOP Orphan Pharmaceuticals AG, preservative-free parenteral treprostinil (NCT06350032)
- 2024-04-02Results posted on the registry: Duke University, Iloprost and nitric oxide administration (NCT03044314)
- 2024-04-02Also stopped (terminated): Duke University, Iloprost and nitric oxide administration (NCT03044314)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision